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Summary
Objective: Male New Zealand black/KN (NZB/KN) mice spontaneously develop polyarthritis, characterized by destructive damages to the
articular cartilage and bone. We assessed effects of diacerein in male NZB/KN mice by radiographic and histopathologic examinations.
Design: Diacerein, cyclosporin A or vehicle for the control were orally administered for 7 months, initiating at 8 weeks of age when the arthritis
became apparent.
Results: At 39 weeks of age, the NZB/KN mice developed polyarthritis in the joints of the forelimbs and hind legs, radiographically
characterized by joint space narrowing, deformation of the joint surfaces, and bone erosions. Histopathologic findings showed that the tarsal
joints and knee sections from the NZB/KN mice exhibited overt arthritic lesion. Radiographic and histopathologic findings showed that
diacerein and cyclosporin A at a dose of 30 mg/kg/day significantly reduced the progression of arthritis.
Conclusions: Diacerein shows articular protecting effects against the development of spontaneous arthritis in male NZB/KN mice and
diacerein might be useful in the treatment of chronic inflammatory joint diseases during clinical use. © 1999 OsteoArthritis Research Society
International
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Male New Zealand black/KN (NZB/KN) strain is a subline of
NZB/San, which was bred at the Medical Science Institute,
Tokyo University, and donated to Kitasato University
School of Medicine. In male NZB/KN mice, joint lesions first
became evident at the age of 2 months, and these changes
became more severe by 14 months of age, and the
histopathologic characteristics showed hypertrophy and
hyperplasia of the synovial lining cells, irregularity of the
joint surfaces caused by pannus formation and erosion of
the cartilage layer.1 Rheumatoid factor and anti-type II
collagen antibodies were also produced, and bone marrow
transplantation prevented polyarthritis in these mice,2
suggesting that immunologic aberrations may be involved
in the pathogenesis of the disease.
Rheumatoid arthritis (RA) is a chronic, systemic auto-
immune disease characterized by joint swelling, synovial
inflammation, and cartilage destruction. Non-steroidal anti-
inflammatory drugs (NSAIDs), steroids, disease-modifying
anti-rheumatic drugs (DMARDs), immunosuppressive
drugs, and combination therapy have been used in the
treatment of RA. There are currently no therapies which
address this aspect of these diseases directly. The devel-533opment of an articular protecting safe drug, based on a
fundamental understanding of RA, is currently needed.3
Clinical studies have suggested that diacerein has a
beneficial effect on the symptoms of OA.4–6 Diacerein has
no effect on prostaglandin biosynthesis but shows anti-
osteoarthritic properties and chondroprotective effects, as
shown previously in animal models.7,8 Diacerein has been
shown to inhibit the migration of leukocytes into inflamed
tissue.9 It also reduces superoxide anion production by
human neutrophils10 and increases hyaluronan syn-
thesis.11 In addition, diacerein inhibits the proinflammatory
effects of interleukin-1 (IL-1) on cultured chondrocytes.12
Diacerein has the protective effect against granuloma-
induced cartilage breakdown by a reduction in the
concentrations of proinflammatory cytokines.13
In the present study, we evaluated the articular protect-
ing effects of diacerein against spontaneous polyarthritis in
male NZB/KN mice by radiographic and histopathologic
examinations.Materials and methodsReceived 1 July 1998; accepted 28 April 1999.
Address correspondence and reprint requests to: Tadafumi
Tamura, Drug Development Research Laboratories, Pharma-
ceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., 1188
Shimotogari, Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731,
Japan.ANIMALS
Male NZB/KN mice were purchased from Omura
Experimental Animal Institute (Kanagawa, Japan). Mice
used in this study were treated in compliance with the
Guiding Principles for the Care and Use of Laboratory
Animals approved by the Japanese Pharmacological
Society, and the experimental protocols were approved
by the ethical committee of Pharmaceutical Research
534 T. Tamura et al.: Diacerein in male NZB/KN miceFig. 1. Radiographs of hindlimb from male BALB/mice and male NZB/KN mice. Drugs were orally administered 5 days a week, for 7 months,
started at 8 weeks of age. (a) Male NZB/KN mice treated with vehicle were characterized by joint space narrowing, deformation of the joint
surfaces, and bone erosions. Male NZB/KN mice treated with diacerein 30 mg/kg/day (b) or with cyclosporin A 30 mg/kg/day (c) reduced thebone destruction.
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kept at 22°C with a 12 h light-dark cycle. They had free
access to tap water and commercial chow.DRUGS
Diacerein was provided by Proter, Milano, Italy.
Cyclosporin A (Sandimmun® injection) was purchased
from Sandoz, Ltd (Berne, Switzerland). Diacerein was
suspended in 5% gum arabic (Wako Pure Chemical
Industries, Osaka, Japan) solution immediately before use
and cyclosporin A was diluted in distilled water immediately
before use for oral administration to mice at a constant
volume of 10 mL/kg body weight. Five percent gum arabic
solution was orally given to control groups. Drugs and
vehicle were orally administered to mice 5 days a week.EXPERIMENTAL SCHEDULE
Diacerein, cyclosporin A or vehicle for the control were
orally administered 5 days a week, for 7 months, started at
8 weeks of age when the arthritis became apparent. To
follow the development of the arthritis, radiographs were
taken at 8, 17, 26, 34 and 39 weeks of age. At the end of
the experiment, mice were observed for histopathologic
changes.RADIOGRAPHIC EVALUATION
Radiographs were taken in a Softex CMB-2 (Softex Co.,
Tokyo, Japan) using Fuji FR X-ray film (Fuji Photo Film Co.,
Tokyo, Japan) under the following conditions: 45 cm dis-
tance; 30 kVp tube voltage; 15 mA tube current; and 20 s
irradiation time. For radiographs, mice were anesthetized
by intraperitoneal injection of pentobarbital (Nembutal®
Injection, Abbott Laboratories, Illinois, USA) at 50 mg/kg
and limbs were taped into position on film carries, and
radiographed as described above. Radiographs were read
under an anatomic microscope. Radiographs were blindly
scored according to the presence or absence of osteolytic
changes, articular abnormalities, deformities of joint sur-
faces and cavities, deformities due to bone fusion, and the
number of bones degraded in the forelimbs, hind legs
(talus, calcaneus, cuneiform, metatarsal, phalanx, tibia,
fibula, knee, ulna, radius etc.) and the tail as previously
1described.HISTOPATHOLOGIC EVALUATION
At the end of the experiment, the forelimbs and hind legs
were fixed in 10% neutral buffered formalin. Following
decalcification, the joints were processed and stained with
haematoxylin and eosin (H&E), with toluidin blue or with
masson trichrome. The histopathologic changes in each
joint were blindly evaluated by scoring a graded scale from
0 to 3 in accordance with a modification of the evaluation
critiera described by Hom et al.;14 0=intact, normal,
0.5=minimal synovitis, primarily featuring the infiltration of
mononuclear inflammatory cells into the synovial mem-
brane, 1=mild synovitis, with no cartilage degeneration or
bone changes, 2=moderate synovitis, with mild cartilage
and bone changes, 3=marked synovial inflammation, fibro-
blast proliferation, cartilage damage and periosteal bony
proliferation. The maximum attainable score was 12.Table I






Control — 8 197.3 (4.8)
Diacerein 30 11 139.8 (6.2)***
Cyclosporin A 30 7 150.7 (5.7)***
Drugs were orally administered 5 days a week, for 7 months,
starting at 8 weeks of age. Radiographs were blindly scored in the
forelimbs, hind legs (talus, calcaneus, cuneiform, metatarsal,
phalanx, tibia, fibula, knee, ulna, radius etc.) and the tail as
described in the method. ***: significantly different from the vehicle
treated control group; P<0.001 (Student’s t-test).Fig. 2. Effects of diacerein and cyclosporin A on radiographic
changes of fore limbs and hind legs in male NZB/KN mice. Mice
were orally administered with vehicle ( , N=8); diacerein, 30 mg/
kg/day ( , N=11); cyclosporin A, 30 mg/kg/day (h, N=7) for
7 months started at 8 weeks of age. Radiographs were blindly
scored in each paw as described in the method. Each point
represents the mean±s.e. ** and ***: significantly different from the
vehicle treated control group; P<0.01 and P<0.001, respectively
(Student’s t-test). †: significantly different from the vehicle treated
control group; P<0.001 (Aspin-Welch test).Table II






Control — 8 198.9 (4.5)
Diacerein 3 4 190.0 (9.1)
10 4 184.8 (12.3)
30 5 130.0 (4.8)***
Diacerein was orally administered 5 days a week, for 7 months,
started at 8 weeks of age. Radiographs were blindly scored in the
forelimbs, hind legs (talus, calcaneus, cuneiform, metatarsal, pha-
lanx, tibia, fibula, knee, ulna, radius etc.) and the tail as described
in the method. ***: significantly different from the vehicle treated
control group; P<0.001 (Scheffe test).STATISTICAL ANALYSIS
The values obtained were expressed as the mean with
standard error for each group. Data from the radiographic

































































































































































































































































Osteoarthritis and Cartilage Vol. 7 No. 6 537evaluation were analysed using either the Scheffe test,
the Student’s t-test or the Aspin-Welch test. Data from
the histopathologic evaluation were analysed using
Mann-Whitney U-test.ResultsRADIOGRAPHIC EVALUATION
At 39 weeks of age, control male NZB/KN mice devel-
oped polyarthritis in the joints of the forelimbs and hind
legs, radiographically characterized by joint space narrow-
ing, deformation of the joint surfaces, and bone erosions
[Fig. 1(a)]. Diacerein or cyclosporin A, used as a positive
control, was orally administered for 7 months initiating at 8
weeks of age. There was no significant difference in body
weight change between control and treated mice (data not
shown). Radiographs showed that diacerein (30 mg/kg/
day) and cyclosporin A (30 mg/kg/day) reduced the pro-
gression of arthritis [Fig. 1(b) and (c)]. Table I showed the
effects of diacerein and cyclosporin A on the radiographic
score of the forelimbs, hind legs and the tail, as regarding
the progression of arthritis, at 39 weeks of age. The
radiographic score of the control group was 197.3±4.8. The
scores of the treated mice were significantly reduced in
both diacerein (139.8±6.2) and cyclosporin A (150.7±5.7)
groups. When the radiographic score of each paw recorded
over time, they showed the similar evolution (Fig. 2).
Next, the dose dependency of the suppressive effect
of diacerein in male NZB/KN mice was examined. Mice
were treated with various doses of diacerein (3, 10 and
30 mg/kg/day) for 7 months starting at 8 weeks of age.
Table II shows that 3 and 10 mg/kg/day dosages had little
or no effect on the radiographic score, but there was a
statistically significant reduction at 30 mg/kg/day.HISTOLOGICAL EVALUATION
At 39 weeks of age, the tarsal joints and forepaw
tissue from control male NZB/KN mice exhibited overt
arthritic lesions; infiltration of mononuclear cells, hyper-
plasia of synovial lining cells and pannus formation
with resulting articular cartilage and subchondral bone
destruction [Fig. 3(a, c)]. In contrast, diacerein (30 mg/kg/
day) treated mice had a lower incidence of arthritic
lesions than control mice [Fig. 3(b, d)] and had a sig-
nificantly suppression of the histopathologic score
(Table III). Cyclosporin A also significantly suppressed the
histopathologic changes.Table III
Histopathological effects of diacerein and cyclosporin A on soft








Control — 8 9.1 (0.2) 9.5 (0.3)
Diacerein 30 11 6.8 (0.5)** 6.2 (0.4)***
Cyclosporin A 30 7 6.4 (0.4)** 5.2 (0.5)***
Drugs were orally administered 5 days a week, for 7 months,
starting at 8 weeks of age. At the end of the experiment, the
forelimbs and hind legs were fixed in 10% neutral buffered forma-
lin. Following decalcification, the joints were processed and
stained with H&E, toluidin blue or masson trichrome. ** and ***:
significantly different from the vehicle treated control group;
P<0.01 and P<0.001, respectively (Mann–Whitney U-test).Discussion
Experimental arthritis models, including adjuvant arthritis
in rats,15 collagen-induced arthritis in rats and mice16 and
spontaneous arthritis in MRL/lpr mice,17 have been widely
employed to study the compounds for RA. Indeed, these
models are considered to resemble RA in terms of
histopathologic features. However, most arthritic ex-
perimental models develop arthritis within a short time,
and it is therefore difficult to assess the long-term effects of
agents such as slow-acting anti-rheumatic drugs. These
models are sensitive to NSAIDs treatment, despite their
lack of effectiveness in preventing joint destruction in RA.18
In male NZB/KN mice, joint lesions first become evident
at the age of 2 months, and these changes become moresevere by 14 months.1 Male NZB/KN mice may be useful in
evaluating anti-rheumatic drugs. However, a wide range of
autoantibodies such as the rheumatoid factor and anti-type
II collagen antibodies are produced in these mice, although
the contribution of autoimmunity to the expression of
arthritic disease is not yet clear. This suggests that
immunologic aberrations may be involved in the patho-
genesis of the disease and their arthritis diseases may
be sensitive to immunosuppressive drugs, such as
SM-8849,19 and DMARDs, sonatimod.20 On the other
hand, these mice are completely insensitive to treatment
using NSAIDs, indomethacin, their lack of effectiveness in
preventing joint destruction in RA.19
Diacerein has proved to be effective and well tolerated in
the long-term treatment of OA.4–6 Diacerein reveals a
somewhat particular clinical profile, in the sense that its
activity takes effect slowly, and is prolonged for some time
after the suspension of treatment. In this study, we investi-
gated the effect of diacerein and cyclosporin A in male
NZB/KN mice. Diacerein reduced the development and
progression of radiographic score, showing significant
reduction at a dose of 30 mg/kg/day for 7 months. Diac-
erein significantly suppressed the histopathological
changes in the tarsal joints and knee sections. Cyclosporin
A also significantly suppressed the radiogrpahic score and
histopathological changes at a dose of 30 mg/kg/day.
Autoimmune-prone mice show increases in circulating
immune complex and anti-single-stranded DNA (anti-
ssDNA) antibodies with age. We measured anti-type II
collagen antibodies and anti-ssDNA antibody by enzyme-
linked immunosorbent assay. There was no significant
difference in these antibody between control and treated
mice (data not shown).
The effect of diacerein seems to be mediated by an
action on several of the inflammatory mechanisms.21 The
mechanism of action of diacerein is different from that
described for classic NSAIDs or steroids. Diacerein
has no effect on phospholipase A2, cyclooxygenase or
5-lipoxygenase, but has been shown to stimulate synthesis
of prostaglandin E2 by chondrocytes in culture and to inhibit
expression of collagenase by chondrocytes exposed to
IL-1.22–26 Rhein, an active metabolite of diacerein, inhibits
the phagocytic activity of neutrophils and macrophages,27
and inhibits the superoxide production by stimulated neu-
trophils.6,7 In addition, rhein affects the release and the
activity of lysosomal enzymes of activated PMNs, and
moderately inhibits their chemotaxis.28 Such evidence
indicates that the chondroprotective effect by diacerein may
538 T. Tamura et al.: Diacerein in male NZB/KN micecontribute to suppression of articular damage in male
NZB/KN mice. However, further studies may be necessary
to determine whether the inhibitory action of diacerein is
associated with the immunoregulatory action.
In the present study, we investigated the prophylactic
effects of diacerein on the development of spontaneous
arthritis in male NZB/KN mice to obtain further insight
into the clinical application of this medication. Conse-
quently, diacerein has the effect to modify underlying dis-
ease processes which occur in both OA and RA, thereby
maintaining long-term joint function.References
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